Long-term outcomes of biological therapy in Crohn's disease complicated with internal fistulizing disease: BIOSCOPE study from GETECCU.
Manuel Barreiro-de AcostaAgnès Fernández-ClotetFrancisco MesoneroFrancisco Javier García-AlonsoMaría José CasanovaMargarita Fernández-de la VargaFiorella CañeteLuisa de CastroAna GutiérrezBeatriz SiciliaVictoria CanoOlga MerinoRuth de FranciscoIrene González-PartidaGerard SurísLeyanira TorrealbaRocío Ferreiro-IglesiasBeatriz CastroLucía MárquezAna SobrinoAinara ElorzaXavier CalvetPilar VarelaRaquel VicenteLuis BujandaLaura LarioNoemí ManceñidoMariana F García-SepulcreEva IglesiasCristina RodríguezMarta PiquerasJuan Ángel Ferrer RosiqueAlfredo J LucendoOlga BenítezMelody GarcíaDavid OlivaresCarlos González-MuñozaBeatriz López-CauceVictor Jair Morales AlvaradoKaterina SpicakovaAlicia BrotonsFernando BermejoPedro AlmelaNahia IspízuaPau GilabertCarlos TardilloFernando MuñozPablo NavarroRosa Eva Madrigal DomínguezPau SendraEsther HinojosaEmpar SáinzMaría Dolores Martín-ArranzDaniel CarpioElena RicartBerta CaballolLaura NúñezJesús BarrioJavier P GisbertMarisa IborraMargalida CalafatVicent HernándezRoser Muñoz PérezJosé Luis CabriadaEugeni DomènechIago Rodriguez-LagoPublished in: The American journal of gastroenterology (2022)
Biologic therapy is beneficial in approximately three quarters of patients with fistulizing CD, achieving fistula closure in 24%. However, around one third still undergo surgery due to refractory disease. Some patient and lesion-related factors can identify patients who will obtain more benefit from these drugs.